Neurotoxin implant
AssigneeAllergan Sales, Inc.
InventorsStephen Donovan, Daniel G. Brady
Life of this patent
Estimating the term…
Abstract
A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.
Claims20
A controlled release system, comprising:
- (a) a polymeric matrix, and;
- (b) a quantity of neurotoxin located within the polymeric matrix, wherein fractional amounts of the neurotoxin can be released from the polymeric matrix over a prolonged period of time without a significant immune system response.
A controlled release system, comprising:
- (a) a polymeric matrix, and;
- (b) between about 10 units and about 20,000 units of a botulinum toxin within the polymeric matrix, wherein fractional amounts of the botulinum toxin can be released from the polymeric matrix over a prolonged period of time extending from about 2 months to about 5 years without a significant immune system response.
A method for making a controlled release system which will not induce a significant immune response, the method comprising the steps of:
- (a) dissolving a polymer in a solvent to form a polymer solution;
- (b) mixing or dispersing a neurotoxin in the polymer solution to form a polymer-neurotoxin mixture, and;
- (c) allowing the polymer-neurotoxin mixture to set or cure, thereby making a controlled release system.
A method for using a continuous system release system, the method comprising injection or implantation of a controlled release system which includes a polymeric matrix and a neurotoxin, thereby treating a movement disorder or a disorder influenced by cholinergic innervation without causing a significant immune system response.
A method for making a metal cation-complexed neurotoxin comprising the steps of:
- (a) forming a solution containing a neurotoxin;
- (b) mixing a multivalent metal cation component with the neurotoxin solution to complex the multivalent metal cation with the neurotoxin, thereby forming a metal cation-complexed neurotoxin suspension, and;
- (c) drying said suspension to form the metal cation-complexed neurotoxin.
Dependencies are inferred from the claim text.